Board of Directors

Dr. Glenn Tong FAICD


Glenn has over 20 years of executive management and Board experience in rapid growth biotech companies where a core focus has been the management of product development in highly regulated environments including: pharmaceuticals, diagnostics and genetically modified crops and pastures.  Glenn has raised and managed over $100M in equity capital and collaborative R&D funding.  Past roles include: CEO and Managing Director of Gordagen Pharmaceuticals Pty Ltd., the Molecular Plant Breeding Cooperative Research Centre and Molecular Plant Breeding Pty Ltd., and AgGenomics Pty Ltd. (a subsidiary of Genetic Technologies Limited, ASX:GTG).  Glenn has a Bachelor of Science (Honours) and PhD (Chemistry) from the University of Melbourne and the Howard Florey Institute of Experimental Physiology and Medicine and is a Graduate and Fellow of the Australian Institute of Company Directors.

Mr Lou Panaccio, CA B.Ec MAICD


Mr Panaccio, a successful healthcare businessman with extensive experience progressing companies from concept to commercialisation, was appointed to the role of non-executive director to Invictus Biotechnology, effective from 4 July 2018.  Mr Panaccio possesses more than 30 years’ executive leadership experience in healthcare services and life sciences, and more than 25 years board-level experience. Mr Panaccio is currently a Non-Executive Director of ASX50 company and one of the world’s largest medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005. In addition, Mr Panaccio is also a Non-Executive Director of Unison Housing Corporation Limited, Non-Executive Chairman of ASX-listed biotechnology companies Avita Medical Limited (ASX:AVH) and Genera Biosystems Limited (ASX:GBI) and Non-Executive Director of Rhythm Biosciences Limited (ASX:RHY).  Mr Panaccio has also served in executive and board roles with Melbourne Pathology Group, Monash IVF Group, Primelife Corporation Limited and other private entities.

Mr Richard Estalella


Richard Estalella is an executive and Board director with over 30 years of experience and a successful track record in the Sports Nutrition, Retail, and Multi-Level Marketing industries.  Richard was the Chief Operating Officer and then President of MusclePharm Corp in the US (OTCQB:MSLP) which during his tenure increased distribution to 50,000 retail outlets and 120 countries along with sales revenue growth from US$67M in 2012 to US$167M in 2015. He oversaw operations, finance and supply chain which included the development of global manufacturing capabilities. Richard has an Associates Arts (graduated with Honours) from Miami-Dade Community College and has completed the Babson College Retail Strategies Program.

Professor Michael Mathai


Michael is an expert in nutritional physiology and neurohumoral mechanisms underpinning the effect of diet, micronutrients and pharmaceuticals on health and disease. His research career started at the Howard Florey Institute of Experimental Physiology and Medicine at the Max-Planck Institute for Physiology and Clinical Research in Germany. In 2008, he received an appointment at Victoria University and is now a Professor in the College of Health and Biomedicine.  Over the last 20 years, his research has been awarded funding from government, philanthropic and industry-related sources and resulted in more than 90 publications, with significant impact in advancing evidence-based interventions for the prevention and treatment of obesity and cardiovascular disease. Past appointments in business include Chief Scientific Officer for Gordagen Pharmaceuticals and a director of both Pacific Oligos Pty Ltd and Gordagen Pharmaceuticals. He has a BSc (Hons) and PhD from the University of Melbourne.

Mr Jeffrey Hanlon, BEc, F.C.A, F.G.I.A. F.A.I.C.D, SF FIN


Mr Jeffrey Hanlon began his career with KPMG Hungerfords and trained as a chartered accountant before transitioning into commercial roles. He is a Fellow of a number of peak professional bodies including: the Institute of Chartered Accountants, the Governance Institute of Australia, the Chartered Institute of Secretaries and Administrators and the Australian Institute of Company Directors. Jeff is a Senior Fellow of the FINSIA.  He holds a Bachelor of Economics from Macquarie University, Graduate Diploma in investment and Finance, Graduate Diploma in Company Secretarial Practises, Graduate of the Institute of Company Directors, Certificate in Governance and Risk Management, is a past presenter for the Securities Institute of Australia, FINSIA and frequent presenter for the Governance Institute of Australia.  Jeff has considerable public and unlisted company experience, held various company secretarial and chief financial officer roles with organisations within the energy, innovative technology, biotech (cell and molecular) and life science sector.  Over his career of 30 years, he has played a pivotal role with SME ASX listed and internationally focused Australian companies in the financial and operational management of the businesses from a start-up venture, to pre and post IPO operations.  Jeff has a successful track record in achieving significant improvement in controls, business planning and strategy, underlying profitability and company value and restructures. He also has considerable experience in corporate governance, capital raising and due diligence documentation.